Current Insights Into The Management Of Discoid Lupus Erythematosus

References

• Lehmann P, Hölzle E, Kind P, Goerz G, Plewig G. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol. 1990;22(2 Pt 1):181–187. doi:10.1016/0190-9622(90)70020-I2179293
   PubMed Web of Science ®Google Scholar
• Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011;64(1):37–48. doi:10.1016/j.jaad.2010.06.02821167404
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. J Am Acad Dermatol. 2011;65(6):e179–e193. doi:10.1016/j.jaad.2010.06.01820739095
   PubMed Web of Science ®Google Scholar
• Samotij D, Szczęch J, Werth VP, et al. Disease severity and prophylactic measures in patients with cutaneous lupus erythematosus: results of a worldwide questionnaire-based study. Postepy Dermatol Alergo. 2018;35(2):192–198. doi:10.5114/ada.2018.75242
   Web of Science ®Google Scholar
• Chasset F, Francès C, Barete S, Amoura Z, Arnaud L. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015;72(4):634–639. doi:10.1016/j.jaad.2014.12.02525648824
   PubMed Web of Science ®Google Scholar
• Wolverton SE. Controversies in dermatologic drug therapy. Dermatol Ther. 2009;22(5):397. doi:10.1111/j.1529-8019.2009.01255.x19845716
   PubMed Web of Science ®Google Scholar
• Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.
   Google Scholar
• Callen JP. Intralesional triamcinolone is effective for discoid lupus erythematosus of the palms and soles. J Rheumatol. 1985;12(3):630–633.4045868
   PubMed Web of Science ®Google Scholar
• Pothinamthong P, Janjumratsang P. A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified cutaneous lupus erythematosus disease area and severity index. J Med Assoc Thai. 2012;95(7):933–940.22919989
   PubMedGoogle Scholar
• Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54–64, 64.e1–e2. doi:10.1016/j.jaad.2010.03.037
   Web of Science ®Google Scholar
• Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol. 2009;34(7):776–780. doi:10.1111/j.1365-2230.2008.03138.x19456797
   PubMed Web of Science ®Google Scholar
• Milam EC, Ramachandran S, Franks AG. Treatment of scarring alopecia in discoid variant of chronic cutaneous lupus erythematosus with tacrolimus lotion, 0.3. JAMA Dermatol. 2015;151(10):1113–1116. doi:10.1001/jamadermatol.2015.134926039539
   PubMed Web of Science ®Google Scholar
• Jones DA. The potential immunomodulatory effects of topical retinoids. Dermatol Online J. 2005;11(1):3.
   PubMedGoogle Scholar
• Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol. 1999;41(6):1049–1050. doi:10.1016/s0190-9622(99)70278-110570404
   PubMed Web of Science ®Google Scholar
• Terao M, Matsui S, Katayama I. Two cases of refractory discoid lupus erythematosus successfully treated with topical tocoretinate. Dermatol Online J. 2011;17(4):15.
   Google Scholar
• Jemec GBE, Ullman S, Goodfield M, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161(6):1365–1370. doi:10.1111/j.1365-2133.2009.09330.x19681862
   PubMed Web of Science ®Google Scholar
• Payne JF. A postgraduate lecture on lupus erythematosus. Clin J. 1894;4:223–229.
   Google Scholar
• Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus. 2002;11:71–81. doi:10.1191/0961203302lu147rr11958581
   PubMed Web of Science ®Google Scholar
• Wahie S, Meggitt SJ. Long-term response to hydroxychloroquine in patients with discoid lupus erythematosus. Br J Dermatol. 2013;169(3):653–659. doi:10.1111/bjd.1237823581274
   PubMed Web of Science ®Google Scholar
• Morand E, McCloud P, Littlejohn G. Continuation of long-term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 1992;51:1318–1321. doi:10.1136/ard.51.12.13181485814
   PubMed Web of Science ®Google Scholar
• Stevens MA, Yeaney GA, Lacomis D. 42-year-old man with discoid lupus and progressive weakness. Brain Pathol. 2009;19:153–156. doi:10.1111/j.1750-3639.2008.00238.x19076781
   PubMed Web of Science ®Google Scholar
• Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis. 2010;13:e11–e15. doi:10.1111/j.1756-185X.2010.01551.x20704603
   PubMed Web of Science ®Google Scholar
• Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE. Long-term evaluation of antimalarial in a Dutch SLE cohort: intolerance and other reasons for non-use. Clin Exp Rheumatol. 2014;32:95–100.24238093
   PubMed Web of Science ®Google Scholar
• Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther. 2007;20:160–174. doi:10.1111/dth.2007.20.issue-417970883
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogue´ B, Leroux G, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49:317–326. doi:10.1007/s12016-015-8469-825672591
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415–422. doi:10.1016/j.ophtha.2010.11.01721292109
   PubMed Web of Science ®Google Scholar
• Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640–3647. doi:10.1002/art.2215917075810
   PubMed Web of Science ®Google Scholar
• Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol. 2018;78(1):107–114.e1. doi:10.1016/j.jaad.2017.08.04529061479
   PubMed Web of Science ®Google Scholar
• Ashinoff R, Werth VP, Franks AG. Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine. J Am Acad Dermatol. 1988;19(5 Pt 2):961–965. doi:10.1016/s0190-9622(88)70259-53192780
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Caughman SW, Klippel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Its use in a patient with systemic lupus erythematosus. Arch Dermatol. 1985;121(10):1323–1325.4037829
   PubMedGoogle Scholar
• Shehade S. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol. 1986;122(4):376–377.
   Google Scholar
• Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127(4):515–522. doi:10.1001/archderm.127.4.5152006876
   PubMedGoogle Scholar
• Garza-Mayers AC, McClurkin M, Smith GP. Review of treatment for discoid lupus erythematosus. Dermatol Ther. 2016;29(4):274–283. doi:10.1111/dth.1235827073142
   PubMed Web of Science ®Google Scholar
• Newton RC, Jorizzo JL, Solomon AR, et al. Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus. Arch Dermatol. 1986;122(2):170–176.3511858
   PubMedGoogle Scholar
• Kuhn A, Patsinakidis N, Luger T. Alitretinoin for cutaneous lupus erythematosus. J Am Acad Dermatol. 2012;67(3):e123–126. doi:10.1016/j.jaad.2011.10.03022890744
   PubMed Web of Science ®Google Scholar
• Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of cutaneous lupus erythematosus: review and assessment of treatment benefits based on oxford centre for evidence-based medicine criteria. J Clin Aesthetic Dermatol. 2013;6(1):27–38.
   Google Scholar
• Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20(3):373–85. doi:10.1016/S0733-8635(02)00016-512170873
   PubMed Web of Science ®Google Scholar
• Bottomley WW, Goodfield MJ. Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol. 1995;133(4):655–656. doi:10.1111/j.1365-2133.1995.tb02726.x7577605
   PubMed Web of Science ®Google Scholar
• Wenzel J, Brahler S, Bauer R, Bieber T, Tuting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157–162. doi:10.1111/bjd.2005.153.issue-116029342
   PubMed Web of Science ®Google Scholar
• Kuhn A, Landmann A, Bonsmann G. Fumaric acid esters: a new therapeutic option for skin manifestations in lupus erythematosus? Br J Dermatol. 2017;176(2):301–302. doi:10.1111/bjd.1493828244075
   PubMed Web of Science ®Google Scholar
• Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27(3):391–404. doi:10.1016/j.berh.2013.07.00824238695
   PubMed Web of Science ®Google Scholar
• Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol. 2001;45(1):142–144. doi:10.1067/mjd.2001.11429711423853
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Obermoser G, Cuadrado MJ, et al. Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol. 2005;23(3):393–396.15971430
   PubMed Web of Science ®Google Scholar
• Frankel HC, Sharon VR, Vleugels RA, Merola JF, Qureshi AA. Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol. 2013;52(11):1407–1409. doi:10.1111/j.1365-4632.2011.05200.x24164159
   PubMedGoogle Scholar
• Duong DJ, Spigel GT, Moxley RT III, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol. 1999;135:1079–1087. doi:10.1001/archderm.135.9.107910490113
   PubMed Web of Science ®Google Scholar
• Cuadrado MJ, Karim Y, Sanna G, et al. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med. 2005;118:246–250. doi:10.1016/j.amjmed.2004.04.03215745722
   PubMed Web of Science ®Google Scholar
• Knop J, Bonsmann G, Happle R, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol. 1983;108(4):461–466. doi:10.1111/j.1365-2133.1983.tb04600.x6838771
   PubMed Web of Science ®Google Scholar
• Kindle SA, Wetter DA, Davis MD, Pittelkow MR, Sciallis GF. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience. Int J Dermatol. 2016;55(8):e431–e439.26873674
   PubMed Web of Science ®Google Scholar
• Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol. 2009;145:303–306. doi:10.1001/archdermatol.2009.3019289762
   PubMedGoogle Scholar
• Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol. 2012;66:571–582. doi:10.1016/j.jaad.2011.01.01521821308
   PubMed Web of Science ®Google Scholar
• Cortes-Hernandez J, Avila G, Vilardell-Tarres M, et al. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther. 2012;14:R265. doi:10.1186/ar411123217273
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus. 2010;19(9):1125–1136. doi:10.1177/096120331037034520693207
   PubMed Web of Science ®Google Scholar
• Bezerra ELM, Vilar MJP, Da Trindade Neto PB, Sato EI. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3073–3078. doi:10.1002/art.2135816200586
   PubMed Web of Science ®Google Scholar
• De Souza A, Strober BE, Merola JF, Oliver S, Franks AG. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012;11(10):1224–1226.23134988
   PubMed Web of Science ®Google Scholar
• Tanasescu C, Balanescu E, Balanescu P, et al. IL-17 in cutaneous lupus erythematosus. Eur J Intern Med. 2010;21(3):202–207. doi:10.1016/j.ejim.2010.03.00420493423
   PubMed Web of Science ®Google Scholar
• Chyuan IT, Tsai TH, Chang TH, et al. Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus. Lupus. 2015;24(6):650–651. doi:10.1177/096120331456107225413358
   PubMed Web of Science ®Google Scholar
• Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus. 2012;21(9):1007–1010. doi:10.1177/096120331244198222438028
   PubMed Web of Science ®Google Scholar
• Dahl C, Johansen C, Kragballe K, et al. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report. Acta Derm Venereol. 2013;93(3):368–369.23038045
   PubMed Web of Science ®Google Scholar
• De Souza A, Ali-Shaw T, Strober BE, Franks AG. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol. 2011;147(8):896–898. doi:10.1001/archdermatol.2011.18521844448
   PubMedGoogle Scholar
• Varada S, Gottlieb AB, Merola JF, Saraiya AR, Tintle SJ. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol. 2015;72(2):253–260. doi:10.1016/j.jaad.2014.10.03825486913
   PubMed Web of Science ®Google Scholar
• Romero-Maté A, García-Donoso C, Hernández-Núñez A, Martínez-Morán C, Moreno-Torres A, Borbujo-Martínez J. Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab. Dermatol Online J. 2017;23(1).
   Google Scholar
• Kahn JS, Deverapalli SC, Rosmarin DM. JAK-TAT signaling pathway inhibition: a role for treatment of discoid lupuserythematosus and dermatomyositis. Int J Dermatol. 2018;57(8):1007–1014. doi:10.1111/ijd.1406429873082
   PubMed Web of Science ®Google Scholar
• Kuhn A, Aberer E, Bata-Csörgo Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermato-logy and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31:389–404. doi:10.1111/jdv.1405327859683
   PubMed Web of Science ®Google Scholar
• Henderson DL, Odom JC. Laser treatment of discoid lupus (case report). Lasers Surg Med. 1986;6:12–5,44-45.
   Web of Science ®Google Scholar
• Gupta G, Roberts DT. Pulsed dye laser treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol. 1999;24:498–499. doi:10.1046/j.1365-2230.1999.00545.x10681174
   PubMed Web of Science ®Google Scholar
• Nunez M, Boixeda P, Miralles ES, de Misa RF, Ledo A. Pulsed dye laser treatment of telangiectatic chronic erythema of cutaneous lupus erythematosus. ArchDermatol. 1996;132:354–355.
   Web of Science ®Google Scholar
• Raulin C, Schmidt C, Hellwig S. Cutaneous lupus erythematosus-treatment with pulsed dye laser. Br J Dermatol. 1999;141:1046–1050. doi:10.1046/j.1365-2133.1999.03203.x10606850
   PubMed Web of Science ®Google Scholar
• Pindado-Ortega C, Alegre-Sánchez A, Pérez-García B, Boixeda P. Reply to: S2k guideline for treatment of cutaneous lupus erythematosus-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV).J Eur Acad Dermatol Venereol. 2019;33(2):e70–e71. doi:10.1111/jdv.1520930098058
   PubMed Web of Science ®Google Scholar
• Kuhn A, Becker-Wegerich PM, Ruzicka T, Lehmann P. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology. 2000;201:175–177. doi:10.1159/00001846711053927
   PubMed Web of Science ®Google Scholar
• Tremblay JF, Carey W. Atrophic facial scars secondary to discoid lupus erythematous: treatment using the Erbium: YAG laser. Dermatol Surg. 2001;27:675–677.11442623
   PubMed Web of Science ®Google Scholar
• Baniandres O, Boixeda P, Belmar P, Perez A. Treatment of lupus erythematosus with pulsed dye laser. Lasers Surg Med. 2003;32:327–330. doi:10.1002/lsm.1016912696102
   PubMed Web of Science ®Google Scholar
• Erceg A, Bovenschen HJ, van de Kerkhof PC, de Jong EM, Seyger MM. Efficacy and safety of pulsed dye laser treatment for cutaneous discoid lupus erythematosus. J Am Acad Dermatol. 2009;60:626–632. doi:10.1016/j.jaad.2008.11.90419293010
   PubMed Web of Science ®Google Scholar
• Ekbäck MP, Troilius A. Laser therapy for refractory discoid lupus erythematosus when everything else has failed. J Cosmet Laser Ther. 2013;15(5):260–265.23607738
   PubMed Web of Science ®Google Scholar
• Zachariae H, Bjerring P, Cramers M. Argon laser treatment of cutaneous vascular lesions in connective tissue diseases. Acta Derm Venereol. 1988;68:179–182.2454005
   PubMed Web of Science ®Google Scholar
• Byun YS, Son JH, Cho YS, et al. Intense Pulsed Light and Q-Switched 1,064-nm Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for the Scarring Lesion of Discoid Lupus Erythematosus. Ann Dermatol. 2017;29(3):331–333. doi:10.5021/ad.2017.29.3.33128566911
   PubMed Web of Science ®Google Scholar
• Debu A, Girard C, Bessis D. Discoid lupus erythematosus successfully treated by photodynamic therapy. Br J Dermatol. 2015;172(3):821–822. doi:10.1111/bjd.1340725219781
   PubMed Web of Science ®Google Scholar
• Fernández-Guarino M, Pérez-García B, Harto A, Jaén P. Discoid lupus erythematosus: good response to treatment with photodynamic therapy. J Eur Acad Dermatol Venereol. 2008;22(9):1142–1143. doi:10.1111/j.1468-3083.2007.02560.x18221338
   PubMed Web of Science ®Google Scholar
• Romero-Maté A, Castaño-Suárez E, García-Donoso C, Martínez-Morán C, Meseguer-Yebra C, Borbujo J. Unsuccessful treatment of recalcitrant cutaneous discoid lupus erythematosus with photodynamic therapy. Photodermatol Photoimmunol Photomed. 2010;26(3):156–158. doi:10.1111/j.1600-0781.2010.00506.x20584256
   PubMed Web of Science ®Google Scholar
• Tenti S, Fabbroni M, Mancini V, Russo F, Galeazzi M, Fioravanti A. Intravenous Immunoglobulins as a new opportunity to treat discoid lupus erythematosus: a case report and review of the literature. Autoimmun Rev. 2018;17(8):791–795. doi:10.1016/j.autrev.2018.02.01029885539
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2013;368(8):777.
   Web of Science ®Google Scholar
• Basyreva LY, Brodsky IB, Gusev AA, et al. The effect of Intravenous Immunoglobulin (IVIG) on\textit{ex vivo} activation of human leukocytes. Hum Antibodies. 2016;24(3–4):39–44. doi:10.3233/HAB-16029328128763
   PubMedGoogle Scholar
• Piette J, Frances C, Roy S, Papo T, Godeau P. High-dose Immuno-globulins in the Treatment of Refractory Cutaneous Lupus-erythematosus-open Trial in 5 Cases. In Philadelphia, PA: Lippincott-Raven; 1995:908.
   Google Scholar
• Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep. 2011;13(4):300. doi:10.1007/s11926-011-0180-z21503694
   PubMed Web of Science ®Google Scholar
• Ruzicka T, Meurer M, Bieber T. Efficiency of acitretin in the treatment of cutaneous lupus erythematosus. Arch Dermatol. 1988;124(6):897–902.2967674
   PubMedGoogle Scholar
• Rodriguez-Castellanos MA, Rubio JB, Gomez JFB, Mendoza AG. Phenytoin in the treatment of discoid lupus erythematosus. Arch Dermatol. 1995;131(5):620–621. doi:10.1001/archderm.131.5.620b
   Google Scholar
• Delaporte E, Catteau B, Sabbagh N, et al. Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases. Ann Dermatol Venereol. 1997;124(2)151–156.9740825
   PubMed Web of Science ®Google Scholar
• Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options: part II. J Am Acad Dermatol. 2011;65(6):e195–e213. doi:10.1016/j.jaad.2010.06.01720800319
   PubMedGoogle Scholar
• Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. JCR J Clin Rheumatol. 2012;18(2):92–95. doi:10.1097/RHU.0b013e31823ecd7322334272
   PubMed Web of Science ®Google Scholar
• Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double‐blind, placebo‐controlled, multiple intravenous, dose‐ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2661–2671. doi:10.1002/art.3809123896980
   PubMed Web of Science ®Google Scholar
• Levine D, Switlyk SA, Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-alpha therapy: a case report with review of the literature. J Drugs Dermatol. 2010;9(10):1283–1287.20941956
   PubMed Web of Science ®Google Scholar
• Werth VP, Fiorentino D, Cohen S, Fivenson D, Hansen C, Zoog S. To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of AMG 811 (anti-IFN-gamma) in subjects with discoid lupus erythematosus. Arthritis Rheum. 2013;65(Suppl 10):1608.
   Google Scholar
• Masek-Hammerman K, Peeva E, Ahmad A, et al. Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus. Clin Exp Immunol. 2016;183:258–270.26376111
   PubMed Web of Science ®Google Scholar